OrbiMed is a leading global investment firm that has been investing in the healthcare industry for over 20 years. With a portfolio spanning biopharmaceuticals, medical devices, diagnostics, and healthcare services, OrbiMed is dedicated to finding groundbreaking innovations that will enhance and prolong human lives. Comprised of over 100 distinguished professionals in the fields of science, medicine, investment, and more, OrbiMed manages a staggering $17 billion in public and private company investments worldwide.

Recognizing the vast potential within the healthcare industry, OrbiMed focuses on long-term growth trends driven by global demographics and scientific advancements. The firm capitalizes on investment opportunities across three strategies: public equity, private equity, and private credit/royalty. The public equity strategy involves investing in various publicly-traded medical companies worldwide, while their private equity strategy focuses on early-stage start-ups and growth equity investments with the aim of building market leaders.

Additionally, OrbiMed provides non-dilutive structured debt capital to commercial-stage healthcare companies and offers solutions to monetize valuable intellectual property through royalty streams. OrbiMed has a rich history characterized by adaptability and growth. Since its founding in 1989, the firm has expanded its footprint across the globe, opening offices in prominent cities such as San Francisco, Hong Kong, and London.

With an extensive track record of nurturing and commercializing successful healthcare companies, OrbiMed continues to drive innovation and shape the future of the industry